Pasithea Therapeutics (KTTA) announced the appointment of Dr. James Lee to its scientific advisory board, SAB, to help guide development of PAS-004 for the treatment of ETS2 pathway inflammatory diseases including inflammatory bowel disease, IBD, ulcerative colitis, Crohn’s disease, primary sclerosing cholangitis and ankylosing spondylitis.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KTTA:
- Pasithea Therapeutics presents updated interim data from Phase 1 PAS-004 study
- Pasithea Therapeutics announces preclinical data on PAS-004
- Pasithea Therapeutics announces initiation of Phase 1/1b study of PAS-004
- 3 Penny Stocks to Watch Now, 5/8/25
- Pasithea Therapeutics Raises $6.3 Million in Stock Offering